GoodRx (NASDAQ:GDRX) Shares Gap Up – What’s Next?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $4.11, but opened at $4.26. GoodRx shares last traded at $4.46, with a volume of 627,638 shares changing hands.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Truist Financial cut their target price on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating for the company in a research note on Thursday, April 10th. Wells Fargo & Company cut their target price on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Tuesday, April 29th. UBS Group cut their target price on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a research note on Tuesday, May 13th. Finally, The Goldman Sachs Group cut their target price on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $6.55.

GoodRx Price Performance

The company’s 50-day simple moving average is $4.25 and its 200-day simple moving average is $4.53. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -151.00, a P/E/G ratio of 2.46 and a beta of 1.16.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm had revenue of $202.97 million during the quarter, compared to the consensus estimate of $202.25 million. During the same period last year, the business posted $0.08 earnings per share. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Research analysts forecast that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Insider Transactions at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm’s stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GDRX. National Bank of Canada FI increased its stake in GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company’s stock valued at $39,000 after acquiring an additional 2,151 shares during the last quarter. Citizens Financial Group Inc. RI bought a new position in GoodRx in the first quarter valued at approximately $44,000. Jump Financial LLC bought a new position in GoodRx in the first quarter valued at approximately $49,000. RPO LLC bought a new position in GoodRx in the fourth quarter valued at approximately $52,000. Finally, Versor Investments LP bought a new position in GoodRx in the fourth quarter valued at approximately $54,000. 63.77% of the stock is owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.